Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(152)
•••
Comment by Hankerchiefon Nov 21, 2019 10:56am
89 Views
Post# 30378177

RE:RE:Metastatic Lung Cancer

RE:RE:Metastatic Lung Cancer
vestor111 wrote: I had a similar thought when a close friend was found to have GBM right after the rat results...

This process is so drawn out.   Once again - where the hell is the FDA?   The HC already approved this and Ph1 showed the compound was very benign...so what is the hold up?   Meanwhile patients have few options. 


I can understasnd the fda not wanting floozy treatments like carrott juice for cancer and the like or anything that would cause outright harm. But TLD 1433 just makes sense scientiffically.  Minimally invasive.  Appears safe.  Easy to use potentially.  And ESPECIALLY in a patient population that are basically given a death sentence (GBM) I just can't see why this can't be more aggressively addressed especially in a patient population where there is literally no hope.  I had a close family member die of GBM just over 2 years ago.  Oh well.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities